Aviva PLC lifted its position in Cooper Companies Inc (NYSE:COO) by 25.1% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 35,297 shares of the medical device company’s stock after acquiring an additional 7,078 shares during the quarter. Aviva PLC owned 0.07% of Cooper Companies worth $9,730,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Harvest Fund Management Co. Ltd acquired a new position in Cooper Companies in the first quarter worth $34,000. Total Clarity Wealth Management Inc. bought a new position in shares of Cooper Companies in the 4th quarter worth about $64,000. CSat Investment Advisory L.P. boosted its holdings in shares of Cooper Companies by 18.5% in the 4th quarter. CSat Investment Advisory L.P. now owns 211 shares of the medical device company’s stock valued at $68,000 after buying an additional 33 shares during the period. Sunbelt Securities Inc. bought a new stake in shares of Cooper Companies during the 4th quarter valued at about $20,643,000. Finally, Manchester Capital Management LLC acquired a new stake in Cooper Companies during the fourth quarter worth about $92,000. Institutional investors and hedge funds own 88.09% of the company’s stock.
A number of equities analysts have commented on the company. Jefferies Financial Group decreased their target price on Cooper Companies from $360.00 to $340.00 and set a “buy” rating for the company in a research note on Wednesday, April 8th. Wells Fargo & Co lowered their price objective on Cooper Companies from $388.00 to $329.00 and set an “overweight” rating for the company in a research note on Thursday, May 21st. Stifel Nicolaus increased their target price on Cooper Companies from $320.00 to $350.00 and gave the stock a “buy” rating in a research report on Friday, March 6th. Robert W. Baird boosted their price target on shares of Cooper Companies from $345.00 to $357.00 and gave the company an “outperform” rating in a report on Friday, March 6th. Finally, KeyCorp lowered their price target on shares of Cooper Companies from $380.00 to $330.00 and set an “overweight” rating for the company in a research report on Tuesday, May 26th. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $335.75.
NYSE:COO traded down $15.90 during midday trading on Thursday, hitting $282.73. 12,332 shares of the stock were exchanged, compared to its average volume of 338,065. The company has a market capitalization of $15.44 billion, a price-to-earnings ratio of 42.13, a P/E/G ratio of 2.75 and a beta of 0.92. The company has a current ratio of 1.14, a quick ratio of 0.58 and a debt-to-equity ratio of 0.37. Cooper Companies Inc has a one year low of $236.68 and a one year high of $365.68. The business has a 50-day moving average price of $300.00 and a two-hundred day moving average price of $314.57.
Cooper Companies (NYSE:COO) last issued its quarterly earnings results on Thursday, June 4th. The medical device company reported $1.51 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.29 by ($0.78). Cooper Companies had a net margin of 13.50% and a return on equity of 14.67%. The firm had revenue of $524.90 million for the quarter, compared to analyst estimates of $604.78 million. During the same quarter last year, the business posted $2.94 earnings per share. The firm’s revenue for the quarter was down 19.7% compared to the same quarter last year. Sell-side analysts forecast that Cooper Companies Inc will post 10.53 EPS for the current fiscal year.
Cooper Companies Profile
The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.
Read More: What is a balanced fund?
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.